CliffBio
small molecule

DIVALPROEX SODIUM

DIVALPROEX SODIUM

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameDIVALPROEX SODIUM
Active ingredientDIVALPROEX SODIUM
StrengthEQ 500MG VALPROIC ACID
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2008
Marketing statusDISCN

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.